Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy

The binding between the immune checkpoints, programmed cell death ligand 1 (PD-L1) and programmed cell death 1 (PD-1), compromises T-cell-mediated immune surveillance. Immune checkpoint therapy using immune checkpoint inhibitors (ICIs) to block PD-L1 on cancer cell membrane or PD-1 on activated T ce...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Theranostics
Autors principals: Cai, Shuxian, Chen, Ziyi, Wang, Yingjie, Wang, Min, Wu, Junye, Tong, Yuhong, Chen, Lanlan, Lu, Chunhua, Yang, Huanghao
Format: Artigo
Idioma:Inglês
Publicat: Ivyspring International Publisher 2021
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7778587/
https://ncbi.nlm.nih.gov/pubmed/33408792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.45777
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars